ArticleEMBO molecular medicine2019
ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.
Open access · goldAbstract read
In one paragraph
Article in EMBO molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
10.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 138 citations in OpenAlex.
- Endothelial ADAM17 facilitates neutrophil migration and pulmonary microvascular permeability in acute lung inflammation.Journal of biomedical science · 2026Article
- The extracellular matrix in inflammation and cancer.Molecular biomedicine · 2026Review
- Review
- LINC01063 promotes colon cancer progression via the miR-134-5p/KRAS axis and serves as a prognostic biomarker.Discover oncology · 2025Article
- Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming.Cell death & disease · 2025Review
- [Research Progress on Interleukin-6 in Screening and Prognosis of Patients with Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- ADAM Proteases in Cancer: Biological Roles, Therapeutic Challenges, and Emerging Opportunities.Cancers · 2025Review
- Review
- IL-6 and Olfactory Dysfunction: Focus on Changes, Effects, and Mechanisms.Mediators of inflammation · 2025Review
- Interlinking pathways: a narrative review on the role of IL-6 in cancer and atherosclerosis.Cardiovascular diagnosis and therapy · 2024Review
- Phosphorylation determines the glucose metabolism reprogramming and tumor-promoting activity of sine oculis homeobox 1.Signal transduction and targeted therapy · 2024Article
- Cytosolic DNA sensor AIM2 promotes KRAS-driven lung cancer independent of inflammasomes.Cancer science · 2024Article
- BIRC3-HSP90B1 Interaction Inhibits Non-Small Cell Lung Cancer Progression through the Extracellular Signal-Regulated Kinase Pathway.ACS omega · 2024Article
- Review
- Redefining metalloproteases specificity through network proteolysis.Trends in molecular medicine · 2024Review
- Intestinal Inflammation and Regeneration-Interdigitating Processes Controlled by Dietary Lipids in Inflammatory Bowel Disease.International journal of molecular sciences · 2024Review
- Predictive Roles of ADAM17 in Patient Survival and Immune Cell Infiltration in Hepatocellular Carcinoma.International journal of molecular sciences · 2023Article
- Targeting IL-6 trans-signalling: past, present and future prospects.Nature reviews. Immunology · 2023Review
- Interleukin-6 in Hepatocellular Carcinoma: A Dualistic Point of View.Biomedicines · 2023Review
- Higher cytotoxic activities of CD8BMC immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 10 institutions in 5 countries.
Mohamed I SaadCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.ORCID 0000-0002-4855-2360
Sultan AlhayyaniCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Louise McLeodCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Liang YuCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Mohammad AlanaziCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Virginie DeswaerteCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Ke TangCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Thierry JardeCancer Program, Monash Biomedicine Discovery Institute, Clayton, Vic., Australia.
Julian A SmithDepartment of Surgery, School of Clinical Sciences at Monash Health, Monash University, Clayton, Vic., Australia.
Zdenka ProdanovicMonash Biobank, Monash Health, Clayton, Vic., Australia.
Michelle D TateCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Jesse J BalicCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
D Neil WatkinsThe Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Jason E CainDepartment of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.
Steven BozinovskiSchool of Health and Biomedical Sciences, RMIT University, Bundoora, Vic., Australia.
Elizabeth AlgarCentre for Cancer Research, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Tomohiro KohmotoDepartment of Human Genetics, Tokushima University Graduate School of Medicine, Tokushima, Japan.
Hiromichi EbiDivision of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Japan.
Walter FerlinNovImmune SA, Geneva, Switzerland.
Christoph GarbersDepartment of Pathology, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany.
Saleela RuwanpuraCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Irit SagiDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Stefan Rose-JohnInstitute of Biochemistry, Christian-Albrechts-University, Kiel, Germany.
Brendan J JenkinsCentre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia brendan.jenkins@hudson.org.au.ORCID 0000-0002-7552-4656
Hudson Institute of Medical Research · AUAichi Cancer Center · JPMonash Health · AUAustralian Regenerative Medicine Institute · AUChristian-Albrechts-Universität zu Kiel · DEGarvan Institute of Medical Research · AULight Chain Bioscience (Switzerland) · CHOtto-von-Guericke-Universität Magdeburg · DERMIT University · AUWeizmann Institute of Science · IL
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncogenic
Indexed as
ADAM17 ProteinAnimalsCell Line, TumorGenotypeHumansLung NeoplasmsMiceMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Mutationp38 Mitogen-Activated Protein KinasesPhosphorylationProto-Oncogene Proteins p21(ras)Receptors, Interleukin-6Signal TransductionADAM17 ProteinADAM17 protein, humanMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3p38 Mitogen-Activated Protein KinasesProto-Oncogene Proteins p21(ras)Receptors, Interleukin-6ADAM17ERK MAPKIL‐6 trans‐signalingKRASlung adenocarcinoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.